This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

An elderly American man has become completely blind after he was prescribed to take Ozempic to manage his type 2 diabetes.

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

New findings from the EXERT study reveal that both low and moderate-high intensity exercise may help preserve cognitive function in older adults with mild memory problems, a major risk factor for ...

Ozempic and similar weight loss drugs are currently at the center of multidistrict litigation over claims that the drugs ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...

Novo Nordisk (NVO) announced on Friday that it has secured a legal victory against compounders selling unauthorized versions ...

Ozempic, originally for type 2 diabetes, has surged in popularity in North America as a weight-loss solution, sparking a ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Lawyers for Todd Engel, 62, filed suit yesterday in New Jersey superior court. According to the complaint, Engel is now ...